Business & Finance
Business and Finance
Business and Finance
Wed, June 15, 2011 
TAMPA, Fla.--([ BUSINESS WIRE ])--PanGenex Corporation (aPanGenexa or athe Companya) (Pink Sheets:PGCX), a nutraceutical and dietary supplement developer; today provided a differentiation of certain of its products that focus on soft tissue calcification.
OMEGANOLa" is the first dietary supplement to combine the health properties of concentrated Omega-3 with the antioxidant and cholesterol balancing properties of tocotrienols. Omeganol delivers double protection to your heart.
LIPIDEMEa" promotes heart and cardiovascular health in four ways by combining the pure, concentrated, and medically proven ingredients Omega-3 fatty acids from fish oil, phytosterols, tocotrienols, and coenzyme Q10. When taken as directed, the ingredients in LIPIDEME have been shown to reduce the risk of heart disease.
About PanGenex Corporation
PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent-pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. PanGenex principal products Calci-Clear, LIPIDEME and Omeganol, address Soft Tissue Calcification (STC), an abnormal hardening or thickening of soft tissues (such as arteries) which is linked to over 50% of chronic diseases and presently affects an estimated 196 million or 60 percent of all Americans. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet at [ www.HeartHealthyWorld.com ].
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
